Saturday 17 October 2026
Export MYGN’s income statement to Excel — free account
Myriad Genetics, Inc.
MYGN Healthcare Diagnostics & Research
Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024. In the quarter to June 2026, revenue fell 10.5%, EPS grew 87.1%, free cash flow grew 43.9% and total debt rose 103.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.98
0.37
−8.51%
Follow MYGN
| Dec '19 | Jun '20 | Dec '20 | Jun '21 | Dec '21 | Jun '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | 4 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.49 | 1.32 | 2.30 | 3.17 | 3.12 | 2.17 | 1.81 | 2.09 | 1.48 | 0.69 |
Altman Z-Score |
— | 0.93 | 1.53 | 3.10 | 3.69 | 1.70 | 2.13 | 1.93 | 1.83 | (1.52) |
Altman Z″-Score (non-manufacturers) |
— | 1.33 | 1.23 | 1.81 | 2.68 | 0.73 | 1.94 | (0.13) | (0.10) | (5.88) |
P/FCF ratio |
24.06 | 16.72 | 29.09 | 36.43 | 3,588.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(1,066.27) | 28.20 | 20.07 | (536.54) | (226.61) | (29.39) | (168.49) | (28.76) | 188.20 | 53.73 |
Beneish M-Score |
— | — | — | — | — | — | — | (3.14) | (3.06) | (5.42) |
P/B ratio |
1.88 | 0.92 | 1.67 | 2.62 | 2.22 | 1.54 | 1.39 | 2.01 | 1.77 | 1.55 |
Price to Tangible BV |
129.04 | 0.00 | 0.00 | 10.02 | 6.63 | 4.46 | 5.61 | 10.75 | 8.15 | 3.49 |
EV/Sales |
2.61 | 1.36 | 2.44 | 3.22 | 2.76 | 2.02 | 1.86 | 1.98 | 1.43 | 0.73 |
EV/EBITDA |
7.95 | 6.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
21.75 | 14.28 | 25.65 | 29.49 | 102.47 | (9.35) | (11.85) | (13.42) | (137.62) | 332.88 |
EV/FCF |
25.21 | 17.13 | 30.83 | 37.00 | 3,176.67 | (8.25) | (8.31) | (8.08) | (31.18) | (23.41) |
Quick Ratio |
— | 1.96 | 1.65 | 2.11 | 2.11 | 1.60 | 1.58 | 1.64 | 1.36 | 1.98 |
Current Ratio |
— | 2.26 | 2.67 | 2.38 | 2.37 | 2.01 | 2.00 | 2.01 | 1.82 | 2.49 |
Net Debt/EBITDA |
0.00 | (0.11) | (1.23) | 5.29 | 2.69 | (0.26) | 1.62 | 0.52 | 11.02 | 2.11 |
Debt/Assets |
0.00% | 15.98% | 15.84% | 5.59% | 0.00% | 9.95% | 0.00% | 3.36% | 3.85% | 16.97% |
Debt/Equity |
— | 0.24 | 0.26 | 0.08 | 0.00 | 0.15 | 0.00 | 0.05 | 0.06 | 0.33 |
Asset Turnover |
1.09 | 0.43 | 0.45 | 0.49 | 0.51 | 0.51 | 0.54 | 0.64 | 0.77 | 0.95 |
Operating CF/Net income |
18.20 | (0.30) | (0.30) | (0.62) | (0.68) | 0.96 | 0.95 | 0.42 | 0.07 | 0.00 |
Capex/Depreciation |
(0.12) | (0.06) | (0.06) | 0.00 | (0.28) | 0.00 | (0.65) | (1.18) | (0.25) | (0.07) |
Interest Coverage |
0.63 | (21.45) | (21.45) | (356.86) | (28.86) | (91.00) | (43.94) | (88.76) | (44.11) | (36.88) |
| 0.00% | (19.88%) | (22.18%) | (2.94%) | (2.81%) | (12.08%) | (12.64%) | (31.55%) | (17.15%) | (68.45%) | |
| 0.59% | (13.45%) | (14.13%) | (1.92%) | (1.99%) | (8.49%) | (8.90%) | (22.45%) | (11.71%) | (42.20%) | |
ROIC |
0.00% | (15.66%) | (15.16%) | 0.00% | (18.93%) | 0.00% | (11.40%) | (23.63%) | (12.09%) | (71.53%) |
Return on Tangible Assets |
0.00% | (89.99%) | (70.20%) | (6.70%) | (8.40%) | (34.46%) | (50.72%) | (95.16%) | (50.66%) | (116.98%) |
Average Days of Receivables |
0.00 | 40.58 | 51.15 | 48.10 | 48.25 | 54.88 | 54.66 | 55.39 | 52.82 | 51.04 |
Research and Development Expense of Revenue |
10.09% | 12.09% | 12.09% | 11.86% | 11.86% | 12.59% | 12.59% | 11.78% | 13.54% | 12.95% |
Selling, General and Administrative Expense of Revenue |
65.40% | 79.44% | 79.44% | 70.27% | 77.87% | 69.02% | 75.87% | 76.06% | 66.86% | 65.20% |
Intangible Assets out of Total Assets |
0.00 | 0.66 | 0.64 | 0.45 | 0.49 | 0.51 | 0.56 | 0.56 | 0.53 | 0.29 |
Share Based Compensation of Revenue |
3.94% | 3.95% | 3.95% | 0.00% | 5.26% | 0.00% | 5.62% | 5.40% | 5.95% | 4.27% |
Graham Net Nets |
(0.07) | (0.18) | (0.10) | 0.03 | 0.06 | 0.07 | (0.03) | (0.03) | (0.02) | (0.01) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(1.32%) | (23.63%) | (15.58%) | (4.48%) | (1.34%) | (1.27%) | (9.11%) | (16.84%) | (10.28%) | (64.08%) |
Free Cash Flow Yield |
4.16% | 5.98% | 3.44% | 2.74% | 0.03% | (11.25%) | (12.33%) | (11.71%) | (3.09%) | (4.50%) |
Revenue per Share |
11.58 | 8.59 | 8.59 | 8.85 | 8.85 | 8.42 | 8.42 | 9.10 | 9.25 | 8.90 |
Operating CF per Share |
1.14 | 0.82 | 0.82 | 0.22 | 0.24 | (1.33) | (1.32) | (1.34) | (0.10) | 0.02 |
Capex per Share |
(0.12) | (0.14) | (0.14) | 0.00 | (0.23) | 0.00 | (0.56) | (0.89) | (0.33) | (0.30) |
Free Cash Flow per Share |
1.02 | 0.68 | 0.68 | 0.22 | 0.01 | (1.33) | (1.88) | (2.22) | (0.42) | (0.28) |
Cash per Share |
0.00 | 2.93 | 2.03 | 4.36 | 4.34 | 1.45 | 1.43 | 1.70 | 1.13 | 1.62 |
Shareholders Equity per Share |
0.00 | 12.36 | 11.86 | 12.41 | 12.41 | 10.99 | 10.99 | 9.46 | 7.74 | 3.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 12.36 | 11.86 | 12.41 | 12.41 | 10.99 | 10.99 | 9.46 | 7.74 | 3.97 |
Free Cash Flow |
75.10 | 50.50 | 50.50 | 17.00 | 0.60 | (107.00) | (151.60) | (184.20) | (38.40) | (25.60) |
Working Capital |
— | 184.70 | 243.50 | 281.00 | 280.50 | 138.00 | 137.40 | 157.70 | 133.90 | 198.80 |
Capital Expenditures |
(8.60) | (10.20) | (10.20) | (18.00) | (18.00) | (45.30) | (45.30) | (73.30) | (29.70) | (27.40) |
Net Current Asset Value |
— | (154.70) | (148.40) | 39.00 | 131.90 | (156.00) | (38.30) | (49.70) | (28.50) | (6.00) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.00 | 0.03 | 0.00 | 0.07 | 0.10 | 0.04 | 0.03 |
Price to Operating Income |
11.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 4.64 | 4.22 | 0.60 | 1.49 | 0.34 | 0.83 | 0.52 | 1.00 | 3.27 |
Cash ROIC |
0.00% | 3.71% | 4.02% | 1.23% | 0.05% | (9.44%) | (15.15%) | (19.14%) | (4.55%) | (4.02%) |
Accounts Receivable Turnover |
0.00 | 6.09 | 7.96 | 7.65 | 7.58 | 7.02 | 6.66 | 6.98 | 7.11 | 6.97 |
Accounts Payable Turnover |
0.00 | 6.77 | 8.82 | 9.83 | 6.63 | 8.30 | 6.99 | 8.65 | 8.68 | 7.96 |
Inventory Turnover |
0.00 | 6.15 | 6.62 | 11.80 | 13.04 | 13.77 | 10.07 | 11.22 | 10.19 | 8.53 |
Average Days of Payables |
0.00 | 42.56 | 40.21 | 44.10 | 54.68 | 43.54 | 52.04 | 39.87 | 46.75 | 44.17 |
Days of Inventory on Hand |
0.00 | 57.07 | 53.15 | 22.05 | 28.26 | 30.03 | 36.32 | 34.00 | 39.80 | 45.05 |
Average Receivables |
— | 104.80 | 80.25 | 90.25 | 91.15 | 96.65 | 101.80 | 107.95 | 117.75 | 118.25 |
Average Payables |
— | 27.50 | 21.10 | 25.25 | 29.80 | 29.30 | 28.90 | 27.30 | 29.05 | 31.15 |
Average Inventory |
— | 30.25 | 28.10 | 21.05 | 15.15 | 17.65 | 20.05 | 21.05 | 24.75 | 29.05 |
Average Assets |
781.35 | 1,483.65 | 1,411.70 | 1,416.40 | 1,367.35 | 1,318.85 | 1,257.85 | 1,172.60 | 1,087.05 | 867.10 |
Average Common Equity |
— | 1,003.55 | 899.60 | 924.50 | 967.90 | 926.90 | 885.90 | 834.50 | 742.15 | 534.55 |
Columns are period end dates